Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 10, 2006

Peakadilly Awarded Grant to Accelerate Biomarker Discovery Platform

  • Peakadilly was awarded a grant extension from the Flanders Government to accelerate the development of its protein biomarker discovery platform. This brings the total value of the grant to $2.2 million.

    “Moving forward,” says Koen Kas, founder and CSO, “our goal is to deliver proof-of-concept for the development of the first high-throughput mass spectrometry-based serum protein profiling assay, as we progress in the development of next-generation molecular diagnostics.”

    This grant will support Peakadilly in expanding its relationships with pharma and diagnostic companies and to accelerate development of its own diagnostic and pharmacodiagnostic products.

    Peakadilly implemented a protein biomarker discovery technology that it says will transform the potential of protein biomarkers in molecular diagnostics and drug discovery and development. The company’s protein biomarker discovery operation is based on its MASStermind™ technology and includes the development of blood sample depletion technologies and chromatographic approaches, as well as mass spectrometry techniques and data interpretation methods.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »